With the FDA approval of a near-infrared version of its Cellvizio endomicroscopy technology, Cellvizio can now be used to perform a broader range of microscopic tissue analysis.
The Cellvizio endomicroscopy technology could be used in conjunction with macroscopic imaging systems in future surgical indications.
Mauna Kea Technologies CEO and founder Sacha Loiseau said: "The FDA clearance of the 785nm wavelength is a key milestone in our long-term product roadmap that is the result of years of technical and pre-clinical development."
"We anticipate that the Cellvizio system operating at this new wavelength will open new imaging possibilities that were previously unexplored and are of particular relevance for many potential applications. We are also excited about the new clinical research avenues and commercial developments this FDA clearance will provide the medical community."
Cellvizio is a probe-based confocal laser endomicroscopy system, which provides physicians and researchers with high-resolution cellular imaging of internal tissues.
